secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001104659-24-056664
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint
--------------------------------------------------------------------------------

- Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.
- Trial did not achieve statistical significance for primary or any secondary endpoints; placebo response was unexpectedly higher than historical studies.
- Company immediately commencing cash preservation measures and reviewing all strategic options for ABP-450 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/0001104659-24-056664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/tm2413422d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-056664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer